

The 43rd Annual San Antonio Breast Cancer Symposium, SABCS 2020 will be held Virtually, December 8 – 12, 2020.

Presentations:

- Fam-trastuzumab deruxtecan-nxki (Enhertu®) Daiichi Sankyo/Astra Zeneca
- Patritumab Deruxtecan (U3-1402; HER3-DXd) Daiichi Sankyo/Astra Zeneca

Abstract	Presentation Details
<p>Fam-trastuzumab deruxtecan-nxki (Enhertu®) Daiichi Sankyo/Astra Zeneca</p>	
<p>Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan in HER2 positive metastatic breast cancer</p>	<p><i>Spotlight Poster Discussion 3</i> (Abstract 1190; PD3-06)</p> <p>Modi, et al. Advances in the Treatment of HER2+ Disease;</p> <p>Wednesday, December 9, 2020 at 6:30 pm CT</p>
<p>Trastuzumab deruxtecan with nivolumab in patients with HER2 expressing advanced breast cancer: a two-part, phase 1b, multicenter, open-label study</p>	<p><i>Spotlight Poster Discussion 3</i> (Abstract 299; PD3-07)</p> <p>Hamilton, et al. Advances in the Treatment of HER2+ Disease;</p> <p>Wednesday, December 9, 2020 at 6:30 pm CT</p>
<p>Novel approach to HER2 quantification: digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to T-DXd, specifically in HER2 low patients</p>	<p><i>Spotlight Poster Discussion 6</i> (Abstract 1130; PD6-01)</p> <p>Gustavson, et al. Novel Approaches to Pathology and Imaging;</p> <p>Thursday, December 10, 2020 at 3:30 pm CT</p>
<p>Trastuzumab deruxtecan vs. trastuzumab emtansine in high risk patients with HER2 positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05)</p> <p>[Trial in Progress]</p>	<p>Poster Presentation (Abstract 323; OT-03-01)</p> <p>Geyer, et al. Ongoing Trials Poster;</p> <p>Wednesday, December 9, 2020 at 8:00 am CT</p>

<p>Trastuzumab deruxtecan vs. investigator's choice chemotherapy in patients with hormone receptor positive, HER2 low metastatic breast cancer whose disease has progressed on endocrine therapy in the metastatic setting: a randomized, phase 3 trial (DESTINY-Breast06)</p> <p>[Trial in Progress]</p>	<p>Poster Presentation (Abstract 1219; OT-03-09)</p> <p>Bardia, et al. Ongoing Trials Poster;</p> <p>Wednesday, December 9, 2020 at 8:00 am CT</p>
<p>Trastuzumab deruxtecan combinations in patients with HER2 positive advanced or metastatic breast cancer: a phase 1b/2 open-label, multicenter, dose finding and dose expansion study (DESTINY-Breast07)</p> <p>[Trial in Progress]</p>	<p>Poster Presentation (Abstract 428; OT-03-04)</p> <p>Andre, et al. Ongoing Trials Poster;</p> <p>Wednesday, December 9, 2020 at 8:00 am CT</p>
<p>Trastuzumab deruxtecan combinations in patients with HER2 low metastatic breast cancer: a phase 1b open-label, multicenter, dose finding and expansion study (DESTINY-Breast08)</p> <p>[Trial in Progress]</p>	<p>Poster Presentation (Abstract 532; OT-03-05)</p> <p>Jhaveri, et al. Ongoing Trials Poster;</p> <p>Wednesday, December 9, 2020 at 8:00 am CT</p>
<p>A real-world evidence study of treatment patterns among patients with HER2 positive metastatic breast cancer (mBC)</p>	<p>Poster Presentation (Abstract 426; PS7-82)</p> <p>Collins, et al. Epidemiology;</p> <p>Wednesday, December 9, 2020 at 8:00 am CT</p>
<p>Patritumab Deruxtecan (HER3 ADC) Daiichi Sankyo/Astra Zeneca</p>	
<p>Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3) directed antibody drug conjugate (ADC), in patients with HER3 expressing metastatic breast cancer (MBC)</p>	<p>Spotlight Poster Discussion 1 (Abstract 814; PD1-09)</p> <p>Krop, et al. Novel Therapeutics;</p> <p>Wednesday, December 9, 2020 at 4:00 pm CT</p>

Last update: December 1, 2020